STUDY OF TRIPTANS ON THE RUSSIAN MARKET
Abstract
The article presents the results of a marketing study of the Russian market for triptans used for migraines during 2019-2023.
The purpose of this work was to study the Russian market of selective agonists of serotonin 5HT1 receptors, assessing its dynamics and import dependence.
Material and methods. Systemic analysis based on specialized literature sources, economic and statistical analysis of the DSM Group drug sales database.
Results. The authors analyzed volume and dynamics of sales of triptans in rubles and packages, dynamics of changes in company shares on the market of anti-migraine drugs, identified market-leading manufacturing companies and trade names of drugs and determined reasons for the import dependence of the Russian market of anti-migraine drugs.
Conclusion. As a result of the systemic analysis, the authors concluded that there was high sales volume of triptans for the reviewed time, and active replacement of imported drugs with domestic ones. The study demonstrated that the pharmaceutical industry pays great attention to the increase of production capacity for manufacturing substances in order to expand the range of production of anti-migraine drugs and implement the policy of Russian independence from the supply of foreign drugs.
About the Authors
A. I. Gavrilova
ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Минздрава России
Russian Federation
Russian Federation
M. S. Balabanov
ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Минздрава России
Russian Federation
Russian Federation
A. A. Khalimova
ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Минздрава России
Russian Federation
Russian Federation
Zh. S. Safronova
ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Минздрава России
Russian Federation
Russian Federation
References
1. Azimova, Yu.E. Triptans: Age of Disease-specific Migraine Treatment 2017;(1); 10-14. (In Russ).
2. Sadokha, K.A., Golovko, A.M. Sovremennye tendentsiiv diagnostike redkikh form golovnoi boli (obzor literatury i klinicheskoe nablyudenie) (Current trends in the diagnosis of rare forms of headache (literature review and clinical observation)). Mezhdunarodnyi nevrologieskii zhurnal (International neurological journal). 2017; 4(90):60-66. (In Russ).
3. Kolbin, A.S., Naprienko, M.V., Artemenko, A.R., Vilyum, I.A., Latysheva, N.V. Socio-economic burden of chronic migraine in Russia. Qualitative clinical practice. 2018.(3):82-86. (In Russ).
4. Headaches. – World Health Organization. URL: https://www.who.int/ru/news-room/fact-sheets/detail/headache-disorders (In Russ).
5. Shahbazyan A.E., Evdokimova E.M., Tabeeva G.R. Clinical analysis of triptans for the relief of migraine attacks. Russian Medical Journal. 2017;9:660-663. (In Russ)
6. The latest generation of triptans in the treatment of migraine: a new domestic drug. Neurology.2017;(9);Vol.25:657-658. (In Russ).
7. The drug Ajovi is an effective treatment for migraine. University Headache Clinic. URL: https://headache.ru/services/preparat-adzhovieffektivnoe-lechenie-migreni (In Russ).
8. Erenumab alleviated migraine symptoms better than nonspecific drugs. N+1. URL: https://nplus1.ru/news/2024/04/01/erenumab (In Russ).
9. The long-awaited breakthrough in the fight against migraine: antibodies prevent attacks of the disease. MEDCONS. URL: https://medconsonline.com/ru/blog/novoe-v-lechenii-migreni (In Russ).
10. Clinical recommendations. Migraine. All-Russian Society of Neurologists, Interregional public organization “Russian Society for the Study of Headache”. Ministry of Health of the Russian Federation. 2021. URL: https://cr.minzdrav.gov.ru/schema/295_2 (In Russ).
11. DSM Group. – Database: website. URL: https://dsm.ru/ (In Russ).
12. Global Use of Medicines 2024. Outlook to 2028. – IQVIA Institute for Human Data Science. [Electronic resource]. URL: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028
13. Khalimova A.A., Orlov A.S., Taube A.A. Analysis of biopharmaceutical manufacturing localization in Russia considering the country of origin of active pharmaceutical ingredients. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2024;14(1):53–61. https://doi.org/10.30895/1991-2919-2024-14-1-53-61 (in Russ.)
14. Yadgarov I.S., Filatova E.G., Golubev V.L., Berdnikova A.V. Relief of migraine attack – hepants. Russian neurological journal. 2022;27(3):5-10. https://doi.org/10.30629/2658-7947-2022-27-3-5-10 (in Russ.).
15. «Reyvau»: a completely new medicine against acute migraine. Mosmedpreparaty. [Electronic resource]. URL: https://mosmedpreparaty.ru/news/18847 (In Russ).
Review
For citations:
Gavrilova A.I., Balabanov M.S., Khalimova A.A., Safronova Zh.S. STUDY OF TRIPTANS ON THE RUSSIAN MARKET. Bashkortostan Medical Journal. 2024;19(6):58-62. (In Russ.)
Views:
29
Email this article 
